Stemline Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 01, 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN
March 23, 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results
March 16, 2017 19:25 ET
|
Stemline Therapeutics
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics to Present at the 29th Annual ROTH Conference
March 10, 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
March 02, 2017 11:31 ET
|
Stemline Therapeutics
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Provides Update on Clinical Programs
February 21, 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Provides Update on Pivotal BPDCN Trial
February 02, 2017 15:24 ET
|
Stemline Therapeutics
NEW YORK, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, provides an update on its...
Stemline Therapeutics Prices $45 Million Public Offering of Common Stock
January 20, 2017 09:00 ET
|
Stemline Therapeutics
NEW YORK, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing...
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
January 19, 2017 16:03 ET
|
Stemline Therapeutics
NEW YORK, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it...
Stemline Therapeutics Announces Date Change for the Company’s Presentation at the 35th Annual J.P. Morgan Healthcare Conference
January 09, 2017 17:15 ET
|
Stemline Therapeutics
NEW YORK, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline’s CEO, will now present at the 35th Annual J.P. Morgan...